Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval – Oncology Nurse Advisor
The active ingredient in Journavx is suzetrigine, a sodium channel blocker.
Related Articles
Risk-Stratified Approaches in Newly Diagnosed Myelofibrosis: Clinical Decision-Making for Intermediate-2 Disease
Panelists discuss how risk stratification tools and patient-specific factors guide treatment selection and timing of interventions for patients with newly diagnosed intermediate 2–risk myelofibrosis, with…
AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.
Bevacizumab Benefits in CRC Persist for Two Years After Initiation
Bevacizumab’s survival benefits in CRC patients persist for about 2 years after starting treatment.
IMM-1-104 Plus Chemo Generates Responses in First-Line Pancreatic Cancer
First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
Zhang et al. investigate immune cell dynamics in TNBC patients treated with paclitaxel, nab-paclitaxel, and combinations with atezolizumab. They identify distinct underlying cellular mechanisms, revealing that…
Gallbladder and Bile Duct Cancers: 4 Things to Know
Although gallbladder and bile duct cancers are different diseases, they’re often discussed together. They each have a connection to bile, a fluid that helps with…
Case Closed: Experts Piece Together the Top Takeaways From the 2025 Gastrointestinal Cancers Symposium
Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.
Osimertinib linked to more therapy-related cardiac events than other TKIs for NSCLC
Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related cardiac events than those treated with other EGFR tyrosine kinase inhibitors.“Despite…
